Osteoporosis Treatment Guidelines
Introduction to Alternative Therapies
- For women with osteoporosis who cannot take or prefer alternatives to Fosamax (alendronate), risedronate, zoledronic acid, and denosumab are the recommended first-line alternatives with strong evidence for reducing fracture risk 1
Bisphosphonate Therapies
- Risedronate (Actonel) reduces vertebral fractures and hip fractures, with dosing options including 5 mg daily, 35 mg weekly, 75 mg on two consecutive days monthly, or 150 mg monthly 1, 2
- Zoledronic Acid (Reclast) reduces vertebral, nonvertebral, and hip fractures, with a dosing regimen of 5 mg IV once yearly for treatment, every two years for prevention 1, 2
- Ibandronate (Boniva) has less evidence for hip fracture reduction compared to other bisphosphonates, with dosing options of 150 mg monthly oral or 3 mg IV every three months 2
Non-Bisphosphonate Therapies
- Denosumab (Prolia) reduces vertebral, nonvertebral, and hip fractures, and is a particularly good option for women with high fracture risk or renal impairment 1, 2
- Teriparatide (Forteo) is an anabolic agent that builds new bone, typically reserved for women with severe osteoporosis or who have had fractures, with a limited therapy duration of 2 years due to safety concerns 2
- Calcitonin has weaker evidence for fracture reduction and should only be considered when women cannot tolerate other treatments 2
Estrogen Receptor Modulators and Estrogen Therapy
- The American College of Physicians strongly recommends against using raloxifene for osteoporosis treatment due to increased risk of thromboembolic events, pulmonary embolism, and hot flashes 1
- Estrogen therapy is not recommended specifically for osteoporosis treatment due to increased risk of breast cancer, cardiovascular events, and thromboembolic events 1
Treatment Considerations
- Calcium and vitamin D supplementation should accompany all osteoporosis treatments, with recommended daily doses of 1,200 mg calcium and 600-800 IU vitamin D for women over 51 years 2, 3
- Treatment duration is typically 5 years for most therapies, after which continuation should be reassessed 1, 3
- Bone density monitoring is not recommended during the initial 5-year treatment period 1
Common Pitfalls in Osteoporosis Management
- Inadequate calcium/vitamin D supplementation is a common pitfall, essential with all osteoporosis medications 3
- Failing to consider renal function when selecting therapy can lead to inappropriate treatment choices, with denosumab preferred in cases of renal impairment 3
- Not recognizing rare but serious side effects like osteonecrosis of the jaw and atypical femoral fractures with long-term bisphosphonate use is a critical consideration 3